PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 51 filers reported holding PROQR THRAPEUTICS N V in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $134,000 | -85.9% | 24,400 | -74.6% | 0.00% | -100.0% |
| Q4 2019 | $953,000 | +426.5% | 96,070 | +208.7% | 0.00% | – |
| Q3 2019 | $181,000 | -48.6% | 31,125 | -19.4% | 0.00% | – |
| Q2 2019 | $352,000 | -39.7% | 38,625 | -8.4% | 0.00% | -100.0% |
| Q1 2019 | $584,000 | -4.7% | 42,145 | +8.0% | 0.00% | 0.0% |
| Q4 2018 | $613,000 | – | 39,010 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 748,861 | $6,815,000 | 2.37% |
| Opus Point Partners Management, LLC | 138,461 | $1,260,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,722,950 | $33,879,000 | 1.81% |
| Kerrisdale Advisers, LLC | 465,580 | $4,237,000 | 1.52% |
| DAFNA Capital Management LLC | 261,521 | $2,380,000 | 0.90% |
| SPHERA FUNDS MANAGEMENT LTD. | 470,000 | $4,277,000 | 0.58% |
| Artal Group S.A. | 1,300,000 | $11,830,000 | 0.48% |
| Orbimed Advisors | 1,382,502 | $12,581,000 | 0.20% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,000 | $511,000 | 0.19% |
| ALTRINSIC GLOBAL ADVISORS LLC | 201,360 | $1,832,000 | 0.08% |